Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ew-Jun Chen"'
Publikováno v:
Radiation Physics and Chemistry. 210:111022
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca54670a580e86d87bd8873851d3f396
https://doi.org/10.1016/j.radphyschem.2023.111022
https://doi.org/10.1016/j.radphyschem.2023.111022
Publikováno v:
Nucl Med Mol Imaging
Tumour-induced osteomalacia is a rare paraneoplastic syndrome that manifests as chronic hypophosphataemia, non-specific bone pain and muscle weakness. It is generally caused by phosphaturic mesenchymal tumour (PMT), which is uncommonly associated wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7858b8ee1c8802f1c286256129a98d87
https://europepmc.org/articles/PMC8140163/
https://europepmc.org/articles/PMC8140163/
Publikováno v:
Clinical nuclear medicine. 45(7)
Recent case reports and series have demonstrated the usefulness of Ga/F-PSMA PET/CT in restaging recurrent renal cancer after nephrectomy. We presented a case of a patient with renal mass who had undergone both F-FDG and Ga-PSMA PET/CT for diagnosis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6be95271a5893d2176230bd265aded4
https://pubmed.ncbi.nlm.nih.gov/32404702
https://pubmed.ncbi.nlm.nih.gov/32404702
Publikováno v:
Radiation Physics and Chemistry. 178:108998
Prostate cancer is one of the most common cancers affecting men. Bone scan is part of the staging modality commonly used to evaluate bone metastasis. A bone scan with diffused increased skeletal tracer uptake relative to soft tissue, combined with fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7190d636b69cfae1a28d186ada1a97c7
https://doi.org/10.1016/j.radphyschem.2020.108998
https://doi.org/10.1016/j.radphyschem.2020.108998
Autor:
Munikumar Reddy Doddareddy, Michael Kassiou, Ew-Jun Chen, Gilles J. Guillemin, Nicolas Dzamko, Athena F Phoa, Lenka Munoz, Benjamin Heng, Madeline E. Kavanagh
Publikováno v:
European journal of medicinal chemistry. 95
LRRK2IN1 is a highly potent inhibitor of leucine-rich repeat kinase 2 (LRRK2, IC50 = 7.9 nM), an established target for treatment of Parkinson's disease. Two LRRK2IN1 analogues 1 and 2 were synthesised which retained LRRK2 inhibitory activity (1: IC5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::257d11a0702905f66987344be9f6c3aa
https://pubmed.ncbi.nlm.nih.gov/25791676
https://pubmed.ncbi.nlm.nih.gov/25791676